.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Julphar
Harvard Business School
Boehringer Ingelheim
Novartis
Express Scripts
Teva
Dow
Colorcon
QuintilesIMS

Generated: September 25, 2017

DrugPatentWatch Database Preview

Ariad Company Profile

« Back to Dashboard

What is the competitive landscape for ARIAD, and when can generic versions of ARIAD drugs launch?

ARIAD has two approved drugs.

There are six US patents protecting ARIAD drugs.

There are seventy-six patent family members on ARIAD drugs in nineteen countries.

Summary for Applicant: Ariad

Patents:6
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-002Dec 14, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-001Dec 14, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Ariad
ALUNBRIG
brigatinib
TABLET;ORAL208772-002Apr 28, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-001Dec 14, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Ariad
ALUNBRIG
brigatinib
TABLET;ORAL208772-001Apr 28, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-002Dec 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-002Dec 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Ariad
ALUNBRIG
brigatinib
TABLET;ORAL208772-002Apr 28, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Ariad
ICLUSIG
ponatinib hydrochloride
TABLET;ORAL203469-003Apr 23, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Ariad
ALUNBRIG
brigatinib
TABLET;ORAL208772-002Apr 28, 2017RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ariad

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,278,307Monocyclic Heteroaryl compounds► Subscribe
8,778,942Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors► Subscribe
8,470,851Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors► Subscribe
9,090,561Acetylenic heteroaryl compounds► Subscribe
8,461,167Acetylenic heteroaryl compounds► Subscribe
9,278,971Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ariad Drugs

Country Document Number Estimated Expiration
South Korea20090018942► Subscribe
World Intellectual Property Organization (WIPO)2007133560► Subscribe
Australia2016210725► Subscribe
China103435595► Subscribe
Hong Kong1218878► Subscribe
China103467385► Subscribe
Japan5790629► Subscribe
Japan5273037► Subscribe
Canada2723961► Subscribe
BrazilPI0621098► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ariad Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1973545/01Switzerland► SubscribePRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: SWISSMEDIC 63097 12.02.2014
327Luxembourg► SubscribePRODUCT NAME: PONATINIB SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE
2013027,C1973545Lithuania► SubscribePRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: EU/1/13/839/001, 2013 07 03 EU/1/13/839/002, 2013 07 03 EU/1/13/839/003, 2013 07 03 EU/1/13/839/004 20130703
1 5025-2013Slovakia► Subscribe(93) EU/1/13/839/001, EU/1/13/839/002, EU/1/13/839/003, EU/1/13/839/004, 1.7.2013, EU (94) 3.7.2028
0Finland► Subscribe
2013000152Germany► SubscribePRODUCT NAME: PONATINIB "BENZAMID, 3-(2-IMIDAZO(1,2-B)PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYL-1-PIPERAZINYL)METHYL)-3-(TRIFLUORMETHYL)PHENYL)"; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
2013 00066Denmark► SubscribePRODUCT NAME: POATINIB, HERUNDER PONATINIB HYDROCHLORID; REG. NO/DATE: EU/1/13/839/001-004 20130701
2013 00066Denmark► SubscribePRODUCT NAME: PONATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF INCLUDING THE HYDROCHLORIDE SALT THEREOF; REG. NO/DATE: EU/1/13/839/001-004 20130701
13/059Ireland► SubscribePRODUCT NAME: PONATINIB IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
0130033 00093Estonia► SubscribePRODUCT NAME: PONATINIIB;REG NO/DATE: K(2013)4238 (LOPLIK) 01.07.2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Fuji
Accenture
Deloitte
UBS
US Department of Justice
QuintilesIMS
Healthtrust
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot